09:43 AM EST - Acerus Pharmaceuticals Corporation : Announced that it received a waiver letter from SWK Funding LLC related to the required Minimum Revenue Covenant for Q4-2020 in its existing credit facility with Acerus. All other terms and conditions in the SWK loan agreement remain unchanged. Acerus Pharmaceuticals Corporation
shares T.ASP are trading unchanged at $0.04.
